BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,647,453 | -13.1% | 288,636 | +4.2% | 0.02% | -10.5% |
| Q2 2023 | $22,610,612 | +4.5% | 276,989 | -5.0% | 0.02% | 0.0% |
| Q1 2023 | $21,639,220 | -25.0% | 291,673 | -16.2% | 0.02% | -24.0% |
| Q4 2022 | $28,848,207 | +17.4% | 348,072 | +302.1% | 0.02% | +8.7% |
| Q3 2022 | $24,582,000 | -9.0% | 86,557 | +11.1% | 0.02% | -8.0% |
| Q2 2022 | $27,015,000 | -23.1% | 77,933 | -3.9% | 0.02% | -7.4% |
| Q1 2022 | $35,116,000 | -19.8% | 81,091 | -4.2% | 0.03% | -6.9% |
| Q4 2021 | $43,770,000 | +3.4% | 84,606 | -3.2% | 0.03% | -9.4% |
| Q3 2021 | $42,348,000 | +8.1% | 87,392 | +0.4% | 0.03% | +10.3% |
| Q2 2021 | $39,192,000 | +13.8% | 87,043 | -3.5% | 0.03% | +11.5% |
| Q1 2021 | $34,436,000 | +17.3% | 90,164 | -2.4% | 0.03% | +13.0% |
| Q4 2020 | $29,347,000 | +35.4% | 92,417 | +5.6% | 0.02% | +21.1% |
| Q3 2020 | $21,680,000 | -3.6% | 87,516 | +2.8% | 0.02% | -13.6% |
| Q2 2020 | $22,488,000 | +38.7% | 85,158 | -0.4% | 0.02% | +10.0% |
| Q1 2020 | $16,216,000 | -16.8% | 85,516 | -3.7% | 0.02% | +11.1% |
| Q4 2019 | $19,491,000 | +17.2% | 88,793 | +4.5% | 0.02% | +5.9% |
| Q3 2019 | $16,625,000 | +15.6% | 84,967 | +23.2% | 0.02% | 0.0% |
| Q2 2019 | $14,381,000 | +3.7% | 68,977 | -1.3% | 0.02% | 0.0% |
| Q1 2019 | $13,869,000 | +35.0% | 69,851 | -1.6% | 0.02% | +21.4% |
| Q4 2018 | $10,275,000 | -33.9% | 70,996 | -6.8% | 0.01% | -30.0% |
| Q3 2018 | $15,545,000 | +51.3% | 76,158 | +9.7% | 0.02% | +42.9% |
| Q2 2018 | $10,274,000 | -16.6% | 69,443 | -14.8% | 0.01% | -22.2% |
| Q1 2018 | $12,315,000 | +25.2% | 81,536 | +7.4% | 0.02% | +38.5% |
| Q4 2017 | $9,837,000 | +13.0% | 75,930 | +5.5% | 0.01% | 0.0% |
| Q3 2017 | $8,703,000 | +5.8% | 71,993 | +2.8% | 0.01% | 0.0% |
| Q2 2017 | $8,225,000 | +18.6% | 70,000 | +2.6% | 0.01% | +18.2% |
| Q1 2017 | $6,933,000 | -15.8% | 68,200 | -14.9% | 0.01% | -21.4% |
| Q4 2016 | $8,237,000 | -9.0% | 80,100 | -3.1% | 0.01% | -6.7% |
| Q3 2016 | $9,056,000 | -6.6% | 82,700 | -3.8% | 0.02% | -6.2% |
| Q2 2016 | $9,698,000 | +16.1% | 86,000 | -2.7% | 0.02% | +23.1% |
| Q1 2016 | $8,356,000 | +1.2% | 88,400 | -3.6% | 0.01% | 0.0% |
| Q4 2015 | $8,253,000 | -2.7% | 91,700 | 0.0% | 0.01% | -7.1% |
| Q3 2015 | $8,479,000 | -8.9% | 91,700 | -3.0% | 0.01% | 0.0% |
| Q2 2015 | $9,305,000 | +12.7% | 94,500 | +6.7% | 0.01% | +27.3% |
| Q1 2015 | $8,253,000 | 0.0% | 88,600 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $8,253,000 | – | 88,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |